Stock listing
LSE:SCLP Scancell Holdings PLC Share Price
Home listing (LSE) of Scancell Holdings PLC
Follow Scancell Holdings PLC into a list and get an email when it puts out news.
Share price · LSE:SCLP
79.00p GBX (pence) 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- 78.00p – 82.00p GBX (pence)Nov 20, 2026
- Volume
- 113,783 sharesNov 20, 2026
- Market cap
- £107.2M GBPAt the close on Nov 20, 2026 · price × 135.7M shares outstanding
- 52-week range
- 78.00p – 295.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £212,762 GBPMedian day 118,201 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:SCLP · Home | 79.00p GBX (pence) | 0.00 (0.0%) | 113,783 | 80.00p | 82.00p | 78.00p | 79.00p | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:SCLP · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 79.00p | 0.00 | 0.0% | 80.00p | 82.00p | 78.00p | 113,783 | |
| 79.00p | -0.80 | -1.0% | 79.50p | 79.69p | 78.00p | 321,262 | |
| 79.80p | -4.20 | -5.0% | 81.00p | 81.00p | 79.20p | 165,584 | |
| 84.00p | +3.00 | +3.7% | 81.00p | 84.00p | 80.30p | 25,570 | |
| 81.00p | +1.00 | +1.3% | 80.00p | 82.00p | 79.00p | 111,348 | |
| 80.00p | 0.00 | 0.0% | 79.50p | 81.00p | 79.05p | 163,968 | |
| 80.00p | 0.00 | 0.0% | 80.00p | 81.00p | 79.00p | 1,130,672 | |
| 80.00p | -1.00 | -1.2% | 80.50p | 81.00p | 79.20p | 389,750 | |
| 81.00p | -3.00 | -3.6% | 83.00p | 83.00p | 80.00p | 409,378 | |
| 84.00p | +0.20 | +0.2% | 84.00p | 84.00p | 83.05p | 109,194 | |
| 83.80p | -1.20 | -1.4% | 85.50p | 85.99p | 83.80p | 259,372 | |
| 85.00p | -1.40 | -1.6% | 86.50p | 87.00p | 85.00p | 457,960 | |
| 86.40p | -1.60 | -1.8% | 88.00p | 88.00p | 86.00p | 58,269 | |
| 88.00p | +0.60 | +0.7% | 88.00p | 90.00p | 86.00p | 37,514 | |
| 87.40p | -1.60 | -1.8% | 89.00p | 90.00p | 86.50p | 77,114 | |
| 89.00p | 0.00 | 0.0% | 89.00p | 90.00p | 88.00p | 106,170 | |
| 89.00p | 0.00 | 0.0% | 89.00p | 90.00p | 88.31p | 98,494 | |
| 89.00p | -1.00 | -1.1% | 90.00p | 92.00p | 88.00p | 659,867 | |
| 90.00p | -1.00 | -1.1% | 91.00p | 92.00p | 88.00p | 134,631 | |
| 91.00p | 0.00 | 0.0% | 91.00p | 92.00p | 90.00p | 86,331 | |
| 91.00p | +0.80 | +0.9% | 92.50p | 95.00p | 90.00p | 66,057 | |
| 90.20p | -2.80 | -3.0% | 89.50p | 95.00p | 89.50p | 87,877 | |
| 93.00p | 0.00 | 0.0% | 93.50p | 94.00p | 92.40p | 15,087 | |
| 93.00p | 0.00 | 0.0% | 93.50p | 94.00p | 93.00p | 8,254 | |
| 93.00p | -0.50 | -0.5% | 93.50p | 94.00p | 93.00p | 27,871 | |
| 93.50p | 0.00 | 0.0% | 93.50p | 94.00p | 93.00p | 61,640 | |
| 93.50p | 0.00 | 0.0% | 93.50p | 94.00p | 93.35p | 144,853 | |
| 93.50p | 0.00 | 0.0% | 93.50p | 94.20p | 93.00p | 106,583 | |
| 93.50p | +0.50 | +0.5% | 93.50p | 94.00p | 93.00p | 89,627 | |
| 93.00p | -1.00 | -1.1% | 94.00p | 95.00p | 93.00p | 164,806 | |
| 94.00p | 0.00 | 0.0% | 94.00p | 95.00p | 93.00p | 25,049 | |
| 94.00p | -0.50 | -0.5% | 94.50p | 95.00p | 93.00p | 130,603 | |
| 94.50p | +0.50 | +0.5% | 94.00p | 96.00p | 93.60p | 431,941 | |
| 94.00p | -1.00 | -1.1% | 94.00p | 95.00p | 93.00p | 82,443 | |
| 95.00p | +1.50 | +1.6% | 93.50p | 95.00p | 93.00p | 188,195 | |
| 93.50p | -0.50 | -0.5% | 94.00p | 94.00p | 93.00p | 135,035 | |
| 94.00p | -1.00 | -1.1% | 94.50p | 95.00p | 93.26p | 54,318 | |
| 95.00p | -0.50 | -0.5% | 95.50p | 96.00p | 94.00p | 111,623 | |
| 95.50p | 0.00 | 0.0% | 95.50p | 96.00p | 95.00p | 84,920 | |
| 95.50p | -0.50 | -0.5% | 96.00p | 97.00p | 95.01p | 59,085 | |
| 96.00p | -1.00 | -1.0% | 98.00p | 99.00p | 95.25p | 199,138 | |
| 97.00p | 0.00 | 0.0% | 98.00p | 99.00p | 97.00p | 115,318 | |
| 97.00p | -1.00 | -1.0% | 98.00p | 99.00p | 96.00p | 110,968 | |
| 98.00p | +0.50 | +0.5% | 97.50p | 99.00p | 96.80p | 129,088 | |
| 97.50p | -1.00 | -1.0% | 98.50p | 99.00p | 97.00p | 140,299 | |
| 98.50p | -0.50 | -0.5% | 98.50p | 99.20p | 98.00p | 88,829 | |
| 99.00p | +0.50 | +0.5% | 98.50p | 99.00p | 98.00p | 92,005 | |
| 98.50p | -1.00 | -1.0% | 99.50p | 102.00p | 98.00p | 103,500 | |
| 99.50p | -2.00 | -2.0% | 101.50p | 101.65p | 98.00p | 165,795 | |
| 101.50p | +0.50 | +0.5% | 100.50p | 102.00p | 100.00p | 1,029,377 | |
| 101.00p | +0.50 | +0.5% | 101.00p | 105.50p | 100.00p | 1,134,292 | |
| 100.50p | +1.50 | +1.5% | 99.00p | 105.00p | 98.00p | 724,681 | |
| 99.00p | +1.00 | +1.0% | 98.00p | 100.00p | 98.00p | 296,682 | |
| 98.00p | +2.40 | +2.5% | 96.00p | 99.00p | 95.90p | 256,517 | |
| 95.60p | +0.10 | +0.1% | 95.50p | 97.00p | 95.00p | 79,104 | |
| 95.50p | -0.50 | -0.5% | 96.00p | 97.00p | 95.35p | 236,125 | |
| 96.00p | 0.00 | 0.0% | 96.00p | 97.00p | 95.00p | 163,009 | |
| 96.00p | -1.50 | -1.5% | 97.50p | 99.00p | 95.00p | 116,642 | |
| 97.50p | +1.30 | +1.4% | 96.00p | 99.00p | 95.65p | 118,201 | |
| 96.20p | -0.80 | -0.8% | 97.00p | 98.00p | 95.00p | 211,026 | |
| 97.00p | 0.00 | 0.0% | 97.00p | 98.00p | 96.00p | 93,174 | |
| 97.00p | -1.00 | -1.0% | 98.00p | 98.20p | 96.30p | 212,988 | |
| 98.00p | +1.00 | +1.0% | 97.00p | 100.00p | 97.00p | 365,063 | |
| 97.00p | +2.00 | +2.1% | 95.50p | 98.00p | 95.00p | 938,933 | |
| 95.00p | -1.00 | -1.0% | 96.00p | 97.00p | 95.00p | 799,523 |
Splits
2 splits since 2011 · LSE:SCLP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 10-for-1 | Split |
- Ticker
- LSE:SCLP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Nov 19, 2026
Result of AGM
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 35 slides
Latest news
Result of AGM
Nov 19, 2026
Closed 79.00p (0.0%) on Nov 20, 2026
Scancell Provides Corporate and Clinical Update
Nov 19, 2026
Closed 79.00p (0.0%) on Nov 20, 2026
Notice of AGM
Oct 23, 2026
Closed 91.00p (0.0%) on Oct 23, 2026
Result of General Meeting
Oct 20, 2026
Closed 93.00p (0.0%) on Oct 20, 2026
Issue of Equity, Director Dealing & Voting Rights
Oct 15, 2026
Closed 93.50p (0.0%) on Oct 15, 2026
Preliminary Results
Oct 9, 2026
Closed 93.00p (-1.1%) on Oct 9, 2026
Notice of GM
Oct 2, 2026
Closed 95.00p (+1.6%) on Oct 2, 2026
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
Sep 24, 2026
Closed 96.00p (-1.0%) on Sep 24, 2026
Scancell to Present at the H.C. Wainwright Sept 26
Sep 3, 2026
Closed 95.50p (-0.5%) on Sep 3, 2026
iSCIB1+ MHRA CTA Approval for Ph3 trial
Aug 19, 2026
Closed 96.00p (+1.1%) on Aug 19, 2026
Scancell Holdings PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 23 in the last 12 months · 334 in all · newest Nov 19, 2026 · oldest 2008
- Calls
- 1 call with a replay · 1 with a transcript · latest Jun 25, 2025
- Decks
- 23 decks · latest August 2026
Where Scancell Holdings PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:SCLP · Home listing · This page | LSE | United Kingdom | GBX |
| OTC:SCNLF | OTC | United States | USD |
| AQUIS:SCLP.GB | AQUIS | United Kingdom | GBX |
| Frankfurt:SCP | Frankfurt | Germany | EUR |
Valuation
Statements: Year to Apr 30, 2026 · price Nov 20, 2026
- Enterprise value
- £118.9M GBP
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Scancell Holdings PLC · LSE:SCLP | US$140.2M | US$155.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT | US$145.3M | −US$46.23M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.49 |
| TYK Medicines, Inc. Class H · HKEX:2410 | US$144.9M | US$137.0M | n/a | n/a | n/a | 3.7× | n/a | 0.6× | n/a |
| Sutro Biopharma, Inc. · NASDAQ:STRO | US$142.8M | US$259.6M | n/a | 5.8× | n/a | n/a | −344.2% | n/a | 1.14 |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.29M | n/a | 29.8× | n/a | 1.4× | n/a | 0.3× | n/a |
| Protara Therapeutics, Inc. · NASDAQ:TARA | US$140.4M | US$15.77M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.12 |
| Cloudbreak Pharma, Inc. · HKEX:2592 | US$140.4M | US$82.03M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Abeona Therapeutics Inc. · NASDAQ:ABEO | US$138.4M | US$15.29M | n/a | 0.4× | n/a | 1.1× | −160.3% | 0.1× | 1.00 |
| Median of the others | US$143.8M | US$32.75M | 2.2× | 1.2× | −190.2% | 0.1× | 1.14 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 300.00 GBX · Analysts' mean
- EPS, year to Apr 2027
- -0.020 · 1 analyst
- Revenue, year to Apr 2027
- 1M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David Schilansky | CFO |
| Mandeep Sehmi | Investor Relations |
Board
| Director | Role |
|---|---|
| Jean-Michel Cosséry | Chair |
| Susan Clement Davies | Director |
| Ursula Ney | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Scancell Holdings (LSE:SCLP) — Clinical and Corporate Update | Wed, Jun 25, 2025 · 6:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Jan 29, 2026 | −0.9% |
| Quarter to Jul 31, 2025 | Sep 11, 2025 | +7.1% |
| Q2 2025 | Jan 30, 2025 | −2.7% |
| Q2 2023 | Jan 25, 2023 · Before open | −8.0% |
| Q1 2023 | Oct 28, 2022 · Before open | +4.3% |
| Q2 2022 | Dec 22, 2021 · Before open | −1.3% |
| Q1 2022 | Oct 29, 2021 · Before open | −1.3% |
| Q2 2021 | Jan 29, 2021 · Before open | −5.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 35 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 35 slides | July 2026 |
| H1 FY2026 Earnings Presentation | Earnings | 18 slides | Jan 29, 2026 |
| Technical Presentation (December 2025) | Technical | 25 slides | Dec 11, 2025 |
| ESMO Immuno-Oncology Congress 2025 | Conference | 25 slides | Dec 10, 2025 |
| Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting 2025 | Conference | 16 slides | November 2025 |
| H1 FY2025 Earnings Presentation | Earnings | 27 slides | January 2025 |
| FY2024 Earnings Presentation | Earnings | 20 slides | Sep 24, 2024 |
| Shareholder Meeting (November 2023) | Shareholder meeting | 26 slides | November 2023 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 41 slides | November 2021 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| LSX World Congress 2020 | Conference | 21 slides | February 2020 |
| Shareholder Meeting (September 2019) | Shareholder meeting | 18 slides | Sep 12, 2019 |
| Proactive One2One Investor Forum (April 2019) | Conference | 27 slides | Apr 25, 2019 |
| LSX Inv€$tival Showcase 2018 | Conference | 20 slides | Nov 13, 2018 |
| China Healthcare Summit 2018 | Conference | 20 slides | November 2018 |
| Proactive One2One Biotechnology Forum (November 2018) | Conference | 27 slides | November 2018 |
| Shareholder Meeting (October 2018) | Shareholder meeting | 38 slides | Oct 30, 2018 |
| Investor Presentation (February 2018) | Investor deck | 58 slides | Feb 16, 2018 |
| Shareholder Meeting (October 2017) | Shareholder meeting | 14 slides | Oct 10, 2017 |
| Shareholder Meeting (October 2016) | Shareholder meeting | 17 slides | Oct 18, 2016 |
| Shareholder Meeting (October 2015) | Shareholder meeting | 20 slides | Oct 20, 2015 |
| Shareholder Meeting (November 2012) | Shareholder meeting | 8 slides | Nov 6, 2012 |
| Investor Presentation (March 2012) | Investor deck | 22 slides | Mar 13, 2012 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of private placement (PIPE Financing) Update: US$39.1M · US$0.1205 a share · Leerink Partners +2 Dealers: Leerink Partners, TD Cowen, H.C. Wainwright & Co. Buyers: Redmile Funds (44,813,278 Non-Voting Ordinary Shares); Vulpes (9,128,630 ADSs (representing 91,286,307 Ordinary Shares)); Dr Phil L'Huillier (24,896 ADSs) Insiders: CEO Dr Phil L'Huillier to subscribe for 24,896 ADSs; related parties Redmile Funds and Vulpes also participating Use of proceeds: Fund the registrational Phase 3 study of iSCIB1+ in advanced melanoma through key clinical milestones | Oct 9, 2026 | |
| Loan facility, partly convertible into Ordinary Shares, with warrants Update: up to US$25M · warrants to subscribe for Ordinary Shares pro-rata to drawdowns, equal to 4.5% of each… Buyers: BlackRock (lender under a loan facility of up to $25.0 million); funds and accounts managed by BlackRock (Lender under loan facility of up to US$25,000,000); Kreos Capital VIII Aggregator SCSp (Warrants pro rata to drawdowns under the Loan Facility) Use of proceeds: To initiate and execute the global registrational Phase 3 trial of lead programme iSCIB1+ | Oct 9, 2026 | |
| Private placement of new Ordinary Shares Update: about US$12M · GBX 9 a share · Panmure Liberum Limited Dealers: Panmure Liberum Limited (lead) | Jul 24, 2026 | |
| Ordinary Shares Update: up to US$3M · GBX 9 a share | Jul 24, 2026 | |
| New ordinary shares (Retail Offer Shares) Closed: £1M raised · GBX 10.5 a share · Winterflood Securities Limited Dealers: Winterflood Securities Limited Use of proceeds: Further working capital and balance sheet strength | Dec 9, 2024 | US$1.28M |
| Private placement of new ordinary shares (Placing Shares) Made bigger: £10.3M · GBX 10.5 a share · Panmure Liberum Limited +1 Dealers: Panmure Liberum Limited (co-lead), WG Partners LLP (co-lead) Buyers: Redmile Group, LLC (28,571,428 Placing Shares); Vulpes Investment Management (10,476,190 Placing Shares) Insiders: Related parties Redmile and Vulpes, substantial shareholders, conditionally subscribing for 28,571,428 and 10,476,190 Placing Shares respectively Use of proceeds: Progress lead cancer vaccine SCIB1 and next generation iSCIB1+, and extend cash runway to H2 2026 | Dec 5, 2024 | US$13.13M |
| Private placement of new ordinary shares (Subscription Shares) Update: about £20,000 · GBX 10.5 a share Buyers: Sath Nirmalananthan (190,476 Ordinary Shares) Insiders: Director and CFO Sath Nirmalananthan conditionally subscribed for 190,476 Ordinary Shares | Dec 5, 2024 | US$25,395 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 4.71M | 0 | 5.27M | 0 | 0 | 0 | 0 | 0 | |
| Cost of revenue | 672.0K | 1.12M | 966.0K | 525.0K | 740.0K | 249.0K | 43.0K | 21.1K | 27.6K | 32.6K |
| Gross profit | -672.0K | 3.59M | -966.0K | 4.75M | -740.0K | -249.0K | -43.0K | -21.1K | -27.6K | -32.6K |
| Research and development | 12.0M | 14.7M | 12.9M | 11.6M | 9.48M | 6.41M | 4.67M | 4.15M | 2.85M | 2.77M |
| Selling, general and administrative | 5.39M | 4.79M | 5.40M | 5.02M | 4.79M | 3.35M | 2.12M | 2.58M | 2.09M | 1.78M |
| Operating income | -17.4M | -15.0M | -18.3M | -11.9M | -14.3M | -9.75M | -6.78M | -6.73M | -4.94M | -4.55M |
| Depreciation and amortization | 672.0K | 879.0K | 966.0K | 902.0K | 740.0K | 249.0K | 43.0K | 21.1K | 27.6K | 32.6K |
| EBITDA | -16.8M | -14.1M | -17.3M | -11.0M | -13.5M | -9.50M | -6.74M | -6.71M | -4.91M | -4.52M |
| Interest expense | 1.96M | 1.72M | 1.09M | 1.22M | 2.88M | 1.65M | 14.0K | 0 | 0 | 0 |
| Income before tax | -20.2M | -15.3M | -9.12M | -14.3M | -6.27M | -16.8M | -6.77M | -6.71M | -4.94M | -4.50M |
| Income tax | -2.33M | -3.03M | -3.26M | -2.37M | -1.70M | -1.33M | -1.26M | -1.09M | -745.0K | -950.0K |
| Net income | -17.9M | -12.3M | -5.86M | -11.9M | -2.06M | -15.5M | -5.51M | -5.63M | -4.20M | -3.54M |
| Earnings per share, basic | -0.17 | -0.13 | -0.07 | -0.15 | -0.03 | -0.23 | -0.12 | -0.14 | -0.13 | -0.13 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.32M | 16.9M | 14.8M | 19.9M | 41.1M | 41.1M | 4.56M | 4.56M | 10.3M | 2.67M |
| Receivables | 3.08M | 3.73M | 5.85M | 4.28M | 647.0K | 968.0K | 1.33M | 2.02M | 793.7K | 810.7K |
| Inventory | 533.0K | -79.0K | -1.93M | -1.33M | -793.7K | -810.7K | ||||
| Current assets | 8.40M | 20.6M | 21.9M | 24.6M | 32.4M | 44.7M | 7.07M | 7.07M | 11.1M | 3.52M |
| Property, plant and equipment | 2.74M | 975.0K | 195.0K | 58.0K | 76.9K | 93.1K | ||||
| Goodwill | 3.42M | 3.42M | 3.42M | 3.42M | 3.42M | 3.42M | 3.42M | |||
| Total assets | 10.4M | 23.1M | 23.6M | 30.3M | 49.1M | 8.82M | 10.5M | 10.5M | 14.6M | 7.03M |
| Accounts payable | 821.0K | 606.0K | 1.46M | 1.31M | 2.14M | 821.0K | 395.0K | 716.0K | 356.3K | 274.7K |
| Current liabilities | 29.7M | 26.8M | 6.39M | 3.28M | 2.29M | 2.29M | 1.21M | 1.21M | 696.1K | 531.9K |
| Long-term debt | 0 | 17.4M | 18.5M | 7.01M | 15.2M | 0 | ||||
| Total debt | 17.1M | 16.3M | 19.9M | 21.1M | 18.9M | 15.4M | 129.0K | |||
| Total liabilities | 29.8M | 26.9M | 27.1M | 36.5M | 29.6M | 1.17M | 1.21M | 1.21M | 696.1K | 531.9K |
| Shareholders' equity | -19.4M | -3.83M | -3.50M | -6.23M | 18.1M | 19.5M | 9.34M | 9.34M | 13.9M | 6.50M |
| Shares outstanding | 103.8M | 97.0M | 86.2M | 81.6M | 81.6M | 67.9M | 46.6M | 39.5M | 31.9M | 26.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.6M | -6.11M | -15.7M | -8.14M | -7.80M | -7.80M | -7.03M | -7.02M | -4.06M | -3.85M |
| Capital spending | -94.0K | -14.0K | -177.0K | -203.0K | -744.0K | -27.0K | -2.66K | -2.66K | -11.4K | -61.1K |
| Free cash flow | -10.6M | -6.12M | -15.8M | -8.34M | -8.55M | -4.80M | -7.04M | -7.02M | -4.07M | -3.91M |
| Cash from investing | 356.0K | -1.54M | 178.0K | 81.0K | -741.0K | -13.0K | 12.3K | -2.66K | -8.66K | -7.63K |
| Cash from financing | -1.35M | 9.73M | 10.4M | -746.0K | 46.1M | 46.1M | 1.28M | 1.28M | 11.7M | 11.7M |
| Share buybacks | 24.1M | 3.88M | 1.36M | 12.5M | ||||||
| Change in cash | -11.6M | 2.08M | -5.10M | -8.80M | 37.5M | -985.0K | -5.74M | -5.74M | 7.63M | -3.86M |
Filings
Cap table
Built by 6ix from Scancell Holdings PLC’s releases · as of Dec 9, 2024
- Common shares
- 135,667,513
- Fully diluted
- 135,667,513
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 135,667,513 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 135,667,513 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Schilansky | CFO · Since at least Oct 15, 2026 |
| Jean-Michel Cosséry | Chair · Since at least Oct 15, 2026 |
| Mandeep Sehmi | Investor Relations · Since at least Jul 24, 2026 |
| Susan Clement Davies | Director · Since at least Jul 24, 2026 |
| Ursula Ney | Director · Since at least Jul 24, 2026 |
Log in to ask 6ix AI your own questions about Scancell Holdings PLC.